The goal of this clinical trial is to evaluate the safety and efficacy of coenzyme Q10 supplementation in pediatric patients with SLE. The main questions it aims to answer are: * What is the impact of coenzyme Q10 supplementation on mitochondrial dysfunction? * Does it have a beneficial effect on disease activity through assessment of the systemic lupus erythematosus disease activity index (SLEDAI) score? Researchers will compare the group of patients that take coenzyme Q10 to a group that doesn't to see if coenzyme Q10 supplementation works to decrease mitochondrial dysfunction and disease activity. Participants will: Take coenzyme Q10 plus the standard treatment of SLE or the standard treatment only every day for 3 months. Visit the clinic once every 4 weeks for checkups and tests.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Coenzyme Q10 100 mg capsule once daily for 3 months
The Pediatric Allergy, Immunology and Rheumatology Unit, Ain Shams University Hospitals.
Cairo, Egypt
Mitochondrial dysfunction
Through assessment of the NLRP3 inflammasome and type 1 IFN (IFN-α).
Time frame: 3 months
systemic lupus erythematosus disease activity index (SLEDAI) score.
Determine its possible beneficial effect on disease activity through assessment of systemic lupus erythematosus disease activity index (SLEDAI) score.
Time frame: 3 months
The safety and tolerability of Coenzyme Q10
Assess the safety and tolerability of Coenzyme Q10 supplementation in pediatric SLE patients.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.